

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

- 1-29. (cancelled)
30. (new) A kit comprising:
- a) a first container comprising a unit dosage injectable formulation comprising an effective amount of a nitric oxide donor or nitric oxide agonist for increasing insulin sensitivity to a normal level; and
  - b) a second container comprising an oral dosage formulation comprising an effective amount of a nitric oxide donor or nitric oxide agonist for maintaining insulin sensitivity.
31. (new) The kit of claim 30, wherein the nitric oxide donor or nitric oxide agonist of (a) or (b) is selected from the group consisting of 3-morpholinosyndnonimine (SIN-1), sodium nitrite, nitroprusside, and S-nitroso-N-acetyl-D,L-pencillamine (SNAP).
32. (new) The kit of claim 30, wherein the nitric oxide donor or nitric oxide agonist of (a) or (b) is a pharmaceutically acceptable salt.
33. (new) The kit of claim 30, wherein the oral dosage formulation is a tablet or capsule.
34. (new) The kit of claim 30, wherein the kit comprises more than one tablet or capsule.
35. (new) A method of increasing insulin sensitivity, comprising
- a) administering a unit dosage injectable formulation comprising an effective amount of a nitric oxide donor or nitric oxide agonist for increasing insulin sensitivity; and
  - b) subsequently administering an oral dosage formulation comprising an effective amount of a nitric oxide donor or nitric oxide agonist for maintaining insulin sensitivity.

36. (new) The method of claim 35, wherein the nitric oxide donor or nitric oxide agonist of (a) or (b) is selected from the group consisting of 3-morpholinosyndnonimine (SIN-1), sodium nitrite, nitroprusside, and S-nitroso-N-acetyl-D,L-pencillamine (SNAP).

37. (new) The method of claim 35, wherein the nitric oxide donor or nitric oxide agonist of (a) or (b) is a pharmaceutically acceptable salt.

38. (new) The method of claim 35, wherein the oral dosage formulation is a tablet or capsule.

39. (new) The method of claim 35, wherein the kit comprises more than one tablet or capsule.